单细胞转录组分析揭示t(8;21)急性髓系白血病原始细胞异质性并鉴定新治疗靶点IKZF2
本研究通过单细胞RNA测序刻画t(8;21)急性髓系白血病的瘤内异质性,发现类造血干细胞亚群是最静止且原始的细胞亚群,IKZF2为该亚群的主调控因子,并在t(8;21)急性髓系白血病中较其他亚型上调且受AML1-ETO特异性靶向。在原代样本和小鼠模型中验证IKZF2在原始静止白血病细胞中高富集,敲除IKZF2可阻碍AML1-ETO驱动的异常干细胞积累并促进细胞分化。
要点
- 单细胞RNA测序鉴定类造血干细胞亚群为t(8;21)急性髓系白血病中最静止且原始的亚群。
- IKZF2是类造血干细胞亚群的主调控因子,在t(8;21)急性髓系白血病中较其他亚型上调并被AML1-ETO特异性靶向。
- 敲除IKZF2在体外和体内均阻碍AML1-ETO驱动的异常干细胞积累并促进细胞分化。
核心结论
- 单细胞转录组分析揭示t(8;21)急性髓系白血病的白血病细胞异质性,并发现IKZF2是改善当前治疗策略的潜在靶点。
研究设计与样本
- 研究采用单细胞RNA测序刻画t(8;21)急性髓系白血病的瘤内异质性,并在原代样本和小鼠模型中进行验证。
主要发现
- 类造血干细胞亚群被鉴定为所有白血病细胞群体中最静止且最原始的亚群。
- IKZF2被鉴定为类造血干细胞亚群的主调控因子,在t(8;21)急性髓系白血病中较其他急性髓系白血病亚型上调,并被AML1-ETO特异性靶向。
- 在原代样本和小鼠模型中验证了IKZF2在原始且静止的白血病细胞中高富集。
- IKZF2敲除在体外和体内均阻碍AML1-ETO驱动的异常干细胞积累并促进细胞分化。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The t(8;21)(q22;q22) translocation is one of the most recurrent cytogenetic aberrations in acute myeloid leukaemia (AML). While most patients achieve complete remission, approximately 40% of them still relapse. Early identification and elimination of leukaemia clones with relapse potential could improve prognosis for t(8;21) AML patients. Here, through single-cell RNA sequencing, we characterized the intra-tumoral heterogeneity of t(8;21) AML and identified haematopoietic stem cell (HSC)-like subset as the most quiescent and primitive subgroup among all leukaemia cell populations. Further investigations revealed IKZF2 as the master regulator for HSC-like subset. Notably, IKZF2 was upregulated in t(8;21) AML compared with other AML subtypes and was specifically targeted by AML1-ETO. Using primary samples and mouse models, we verified the high enrichment of IKZF2 in primitive and quiescent leukaemic cells. Moreover, IKZF2 knockout hindered the accumulation of aberrant stem cells driven by AML1-ETO and promoted cellular differentiation both in vitro and in vivo. These facilitate a better understanding of the leukaemia cell heterogeneity in t(8;21) AML and unveil IKZF2 as a potential target for improving current treatment strategies.
引用
- Liu Y, Liu W, Mei Y, et al. Single-cell transcriptome profiling reveals blast cell heterogeneity and identifies novel therapeutic target IKZF2 in t(8;21) acute myeloid leukaemia. Br J Haematol. 2025. PMID: 40781784. doi:10.1111/bjh.70077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。